TABLE 2.

Objective response rate (ORR) for combined immunotherapy and antiangiogenesis therapy with or without chemotherapy.

Group	No. of studies	No. of patients	Pooled values (95% CI), %
Overall	23	1,856	39.0 (31.0–47.0)
A + I	17	968	34.0 (26.0–42.0)
A + I + chemo	6	888	53.0 (45.0–61.0)
First-line therapy
A + I	6	447	52.0 (40.0–64.0)
A + I + chemo	5	696	59.0 (51.0–66.0)
Subsequent-line therapy
A + I	10	500	22.0 (17.0–28.0)
A + I + chemo	2	182	56.0 (30.0–83.0)
Anti-PD-1 therapy
A + I	12	779	37.0 (28.0–45.0)
A + I + chemo	4	461	56.0 (44.0–68.0)
Anti-PD-L1 therapy
A + I	5	189	28.0 (11.0–45.0)
A + I + chemo	2	427	54.0 (19.0–89.0)
Antiangiogenic TKIs
A + I	6	824	35.0 (26.0–43.0)
A + I + chemo	1	13	69.0 (44.0–94.0)
Antiangiogenic mAbs
A + I	11	144	31.0 (11.0–52.0)
A + I + chemo	5	727	55.0 (47.0–67.0)
EGFR mutation-positive
A + I	1	25	32.0 (14.0–50.0)
A + I + chemo	2	182	56.0 (30.0–83.0)
EGFR mutation-negative
A + I	16	943	34.0 (26.0–41.0)
A + I + chemo	5	696	59.0 (51.0–66.0)

95% CI, 95% confidence interval; A + I + chemo, antiangiogenic agents combined with ICIs with chemotherapy; A + I, antiangiogenic agents combined with ICIs; ICIs, immune checkpoint inhibitors; Anti-PD-1, programmed cell death protein-1 inhibitor; Anti-PD-L1, programmed cell death ligand-1 inhibitor; mAbs, monoclonal antibodies; TKIs, small molecule tyrosine kinase inhibitors; ORR, objective response rate.